 Oramed Pharmaceuticals NASDAQ:ORMPs stock had its buy rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Monday, Marketbeat reports. They currently have a 16.00 price objective on the biotechnology companys stock, down from their prior price objective of 20.00. HC Wainwrights target price indicates a potential ... 